Suggested remit: To appraise the clinical and cost effectiveness of pirtobrutinib within its marketing authorisation for relapsed or refractory mantle cell lymphoma.
The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
- Status:
- Suspended
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- TA
- ID number:
- 3975
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 29 March 2024 | Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
| 05 October 2022 | Note added to the project documents |
| 03 August 2022 - 01 September 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 03 August 2022 | In progress. Scoping commenced |
| 31 March 2022 | Note added to the project documents |
| 24 November 2021 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual